icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
See also
Décision d'accès précoce
22/12/2022
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
t2Xjc6WpHBeZY4TW